Related Experiment Video

Updated: Sep 28, 2026

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

Natural progress of blood glucose in full-term low-grade low-birthweight infants

Norio Ishikawa1

  • 1Department of Pediatrics, Yukiguni-Yamato General Hospital, Niigata, Japan. yamato_i@mail.tiara.or.jp

Pediatrics International : Official Journal of the Japan Pediatric Society
|November 8, 2002
PubMed

Insights

Hypoglycemia risk in low-birthweight infants is often overstated. This study found no cases requiring treatment in full-term infants, suggesting frequent blood glucose monitoring is unnecessary for this group.

Area of Science:

  • Neonatal Medicine
  • Pediatric Endocrinology

Background:

  • The clinical significance of hypoglycemia in low-birthweight infants is debated.
  • Existing evidence lacks recent definitions of hypoglycemia.

Purpose of the Study:

  • To assess the risk of hypoglycemia in low-grade low-birthweight infants (LGLBWI).
  • To evaluate the necessity of frequent blood glucose monitoring in LGLBWI.

Main Methods:

  • Whole blood glucose (BGw) was measured in 49 LGLBWI and 38 normal birthweight infants.
  • Measurements were taken at multiple time points after birth and before feeding.

Main Results:

  • Full-term LGLBWI (gestational age 38-40 weeks) showed no lower blood glucose than controls.
  • No LGLBWI required hypoglycemia treatment, even small for gestational age infants.
  • Premature LGLBWI (37 weeks) had transiently lower BGw but normalized without intervention.

Conclusions:

  • Gestational age is a key factor in hypoglycemia risk for LGLBWI.
  • Full-term LGLBWI, including those small for gestational age, do not appear to require intensive glucose monitoring.
  • The risk of significant hypoglycemia in term LGLBWI may be lower than previously assumed.
Abstract

More Related Videos

Monitoring Blood Glucose in Mouse Offspring After Intracytoplasmic Sperm Injection06:11

Monitoring Blood Glucose in Mouse Offspring After Intracytoplasmic Sperm Injection

Published on: May 17, 2024

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo12:17

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo

Published on: August 2, 2017

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...